Expert consensus on the clinical application of antibody‐drug conjugates in the treatment of malignant tumors (2021 edition)

Antibody‐drug conjugates (ADCs) are targeted biological agents composed of a cytotoxic drug linked to a monoclonal antibody through a linker. The monoclonal antibody targets tumor cells and transports small‐molecule cytotoxic drugs for specific delivery and minimal off‐target side effects. It is necessary for clinicians to understand the molecular characteristics and mechanisms of ADCs. Patients' survival mainly depends on the appropriate dose and course of treatment and also on proper management of adverse reactions. This consensus provides a systematic review of commercially available ADCs and further discusses the clinical application and management of ADCs. This consensus summarizes the mechanisms, clinical applications, and safety management of the 14 currently approved antibody‐drug conjugates (ADCs), providing guidance for clinicians to better understand and use these drugs.